| The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-Addicted Non-Small Cell Lung Cancer: a systematic … L Mastrantoni, G Giordano, E Vita, G Horn, J Russo, A Orlandi, G Daniele, ... Cancer Treatment and Research Communications, 100842, 2024 | | 2024 |
| Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies F Lococo, E De Paolis, J Evangelista, A Dell’Amore, D Giannarelli, ... International Journal of Molecular Sciences 25 (17), 9560, 2024 | | 2024 |
| Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis I Gomez-Randulfe, S Silva Díaz, C Escriu, S Mohammed, R Shah, ... Therapeutic Advances in Medical Oncology 16, 17588359241272957, 2024 | | 2024 |
| 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database ML Reale, D Scattolin, E Bria, A Vitale, S Grisanti, J Costa, D Galetta, ... Annals of Oncology 35, S818, 2024 | | 2024 |
| 1301P BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database A Russo, C Sini, DL Cortinovis, LA Muscarella, F Perrone, E Bria, ... Annals of Oncology 35, S828, 2024 | | 2024 |
| 1349P A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020) F Facchinetti, A Camerini, C Bennati, P Bordi, E De Carlo, F Mazzoni, ... Annals of Oncology 35, S852-S853, 2024 | | 2024 |
| MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database ML Reale, F Passiglia, F Cappuzzo, G Minuti, M Occhipinti, A Bulotta, ... ESMO open 9 (9), 103680, 2024 | | 2024 |
| Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success L Belluomini, A Avancini, M Sposito, L Pontolillo, D Tregnago, I Trestini, ... Critical Reviews in Oncology/Hematology 201, 104444, 2024 | | 2024 |
| Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. M Uh, M Perol, K Goto, BJ Solomon, K Park, E Nadal, E Bria, C Martin, ... Journal of Clinical Oncology 42 (23_suppl), 199-199, 2024 | | 2024 |
| Unique Ovarian Metastasis of Small-Cell Lung Cancer and Complete Response After Chemo-Immunotherapy: An Unusual Spread as a Predictor Factor F Monaca, FS Inzani, A Orlandi, E Bria Cureus 16 (8), 2024 | | 2024 |
| Outcomes of Radiotherapy in Oligoprogressive Breast Cancer. F Marazzi, V Masiello, A Orlandi, F Moschella, S Chiesa, A Di Leone, ... Journal of Personalized Medicine 14 (8), 2024 | | 2024 |
| Lazarus Response to Selpercatinib for Bleeding Colic Metastasis in a Patient With RET Fusion-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report F Monaca, E Vita, F Lococo, G Tortora, E Bria Cureus 16 (7), 2024 | | 2024 |
| Intrathoracic Lymph Node Microcalcifications are Associated With a High Prevalence of Malignancy and Anaplastic Lymphoma Kinase Rearrangement: The “Calce” Study F Leoncini, G Sotgiu, A Cancellieri, M Puci, S Cortese, V Livi, J Simonetti, ... Journal of Bronchology & Interventional Pulmonology 31 (3), e0973, 2024 | | 2024 |
| Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients E Giordani, M Allegretti, A Sinibaldi, F Michelotti, G Ferretti, E Ricciardi, ... Journal of Experimental & Clinical Cancer Research 43 (1), 182, 2024 | | 2024 |
| The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors … C Ciccarese, A Anghelone, A Stefani, A Cigliola, A Strusi, F D’Agostino, ... Expert Review of Anticancer Therapy, 1-11, 2024 | | 2024 |
| Chemotherapy Rechallenge or Reintroduction compared to Regorafenib or Trifluridine/Tipiracil for pretreated metastatic colorectal cancer patients: a PROpensity ScorE analysis … MA Calegari, IV Zurlo, E Dell'Aquila, M Basso, A Orlandi, M Bensi, ... Clinical Colorectal Cancer, 2024 | | 2024 |
| Simultaneous Integrated Boost (Sib) Intensity-Modulated Radiotherapy for Treatment of Bone Metastases: Analysis of a Breast Cancer Cohort F Marazzi, V Masiello, A Fabi, S Manfrida, B Corvari, V Lancellotta, ... Preprints, 2024 | | 2024 |
| CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer M Pérol, BJ Solomon, K Goto, K Park, E Nadal, E Bria, C Martin, J Bar, ... Journal of Clinical Oncology, JCO. 24.00724, 2024 | 2 | 2024 |
| To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase … A Orlandi, L Mastrantoni, E Bria, G Tortora Annals of Oncology, 2024 | | 2024 |
| Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer. M Aldea, A Marinello, I Monnet, H de Saint Basile, S Cousin, ... Journal of Clinical Oncology 42 (16_suppl), 8647-8647, 2024 | 1 | 2024 |
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli IRCCS Rome在 policlinicogemelli.it 的电子邮件经过验证
